Form 4: Omeros Director Rajiv Shah Receives Annual Stock Option Grant

Omeros Corporation's Director, Rajiv Shah, was granted an option to purchase 15,000 shares of common stock at an exercise price of $3.20 per share, pursuant to the company's non-employee director compensation policy.

Summary

• Rajiv Shah, a Director of Omeros Corporation (OMER), received an automatic grant of an option to purchase 15,000 shares of common stock.
• The grant was made on June 27, 2025, in conjunction with the company's annual meeting of shareholders.
• The exercise price for these stock options is $3.20 per share.
• The option will fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders, contingent on Mr. Shah's continued service as a director.
• The expiration date for this option is June 27, 2035.
• This grant is consistent with Omeros Corporation's non-employee director compensation policy, which provides for an automatic option grant of 15,000 shares to eligible non-employee directors annually.

Sentiment

Score: 6

Explanation: The document reports a routine, expected transaction related to director compensation. It indicates stability in corporate governance and continued commitment from a board member, which is mildly positive, but does not contain information that would significantly alter the company's financial outlook or strategic direction.

Positives

• The grant of stock options to Director Rajiv Shah aligns with Omeros Corporation's established non-employee director compensation policy, indicating consistent corporate governance practices.
• The continued grant of options suggests stability in the board of directors and ongoing commitment from key personnel.
• The vesting schedule incentivizes long-term commitment and alignment of director interests with shareholder value.

Future Outlook

The stock option granted to Director Rajiv Shah is set to fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders, provided he continues his service as a director through that date.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, including biotechnology and pharmaceuticals, serving as a standard component of compensation packages designed to align director interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a widely adopted compensation strategy in the U.S. corporate landscape, particularly within the biotech and pharmaceutical sectors, similar to companies like Amgen Inc. or Gilead Sciences, Inc., which also utilize equity-based compensation to attract and retain qualified board members.
• The specific grant size of 15,000 shares is within the typical range for non-employee director grants at companies of Omeros's market capitalization, though exact figures vary based on company size, industry, and individual compensation philosophies.
• The vesting schedule, tied to continued service, is a standard mechanism to ensure ongoing commitment and oversight from board members, mirroring practices seen in many publicly traded companies.

Related Party Transactions

• The stock option grant to Director Rajiv Shah constitutes a related party transaction, as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value through equity ownership, potentially encouraging decisions that enhance long-term stock performance. It also reflects the company's commitment to standard corporate governance and compensation practices.
• Employees: No direct impact mentioned, but stable board leadership can indirectly benefit overall company stability and direction.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Rajiv Shah's continued service as a director of Omeros Corporation until the day before the 2026 annual meeting of shareholders for the option to fully vest.

Key Dates

Keywords

Omeros Corporation, OMER, Rajiv Shah, Director, Stock Option, SEC Form 4, Insider Transaction, Compensation Policy, Equity Grant, Corporate Governance